iOncologi Inc, a US-based clinical-stage biopharmaceutical company, announced on Friday that it has acquired TargImmune Therapeutics, a Swiss biotechnology company specialising in novel tumour targeted immunotherapies.
The transaction is claimed to improves iOncologi's capabilities in developing immunotherapies for solid tumours. It aligns with the company's broader strategy to expand its therapeutic pipeline, use next-generation RNA-based immunotherapies, and drive innovation in oncology.
As part of the transaction, iOncologi Inc and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99 percent of TargImmune's shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure is intended to ensures the seamless continuation of TargImmune's research into novel tumour-targeted RNA therapies, while benefiting from iOncologi's expanded resources and strategic vision.
Dr Edgardo Rodriguez-Lebron, iOncologi's recently appointed CEO, said: "This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumours. TargImmune's pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring novel treatments to patients with limited therapeutic options."
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
S&E bio's SNE-101 stroke therapy approved for clinical trial
TransCode Therapeutics reports progress in metastatic cancer trial